MUC5B silencing reduces chemo-resistance of MCF-7 breast tumor cells and impairs maturation of dendritic cells

International Journal of Oncology

Volumn 48, Issue 5, 2016, Pages 2113-2123

  García, Enrique P ^a   Tiscornia, Inés ^b   Libisch, Gabriela ^c   Trajtenberg, Felipe ^d   Bollati Fogolín, Mariela ^b   Rodríguez, Ernesto ^a   Noya, Verónica ^a   Chiale, Carolina ^a   Brossard, Natalie ^a   Robello, Carlos ^a,c   Santiñaque, Federico ^e   Folle, Gustavo ^e   Osinaga, Eduardo ^a,d   Freire, Teresa ^a  

^a DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

^b Cell Biology Unit   (Uruguay)

^c Molecular Biology Unit   (Uruguay)

^d INSTITUT PASTEUR DE MONTEVIDEO   (Uruguay)

^e INSTITUTO DE INVESTIGACIONES BIOLÓGICAS CLEMENTE ESTABLE   (Uruguay)

Author keywords

Cancer; Dendritic cells; MUC5B; Mucins

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MUCIN 5B; SHORT HAIRPIN RNA; CYTOKINE; MUC5B PROTEIN, HUMAN;

ARTICLE; BREAST CANCER CELL LINE; CANCER RESISTANCE; CELL ACTIVATION; CELL ADHESION; CELL DIFFERENTIATION; CELL GROWTH; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; GENE SILENCING; HUMAN; HUMAN CELL; MCF 7 CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; APOPTOSIS; BREAST TUMOR; CELL CYCLE; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; IMMUNOLOGY; MCF-7 CELL LINE; METABOLISM;

APOPTOSIS; BREAST NEOPLASMS; CELL ADHESION; CELL CYCLE; CELL DIFFERENTIATION; CELL SURVIVAL; CYTOKINES; DENDRITIC CELLS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE SILENCING; HUMANS; LIPOPOLYSACCHARIDES; MCF-7 CELLS; MUCIN-5B;

EID: 84962549713     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3434     Document Type: Article

References (45)

1. Corfield AP: Mucins: A biologically relevant glycan barrier in mucosal protection. Biochim Biophys Acta 1850: 236-252, 2015.
2. Kufe DW: Mucins in cancer: Function, prognosis and therapy. Nat Rev Cancer 9: 874-885, 2009.
3. Rachagani S, Torres MP, Moniaux N and Batra SK: Current status of mucins in the diagnosis and therapy of cancer. Biofactors 35: 509-527, 2009.
4. Jonckheere N, Skrypek N and Van Seuningen I: Mucins and tumor resistance to chemotherapeutic drugs. Biochim Biophys Acta 1846: 142-151, 2014.
5. Beatson RE, Taylor-Papadimitriou J and Burchell JM: MUC1 immunotherapy. Immunotherapy 2: 305-327, 2010.
6. Kimura T and Finn OJ: MUC1 immunotherapy is here to stay. Expert Opin Biol Ther 13: 35-49, 2013.
7. H äuselmann I and Borsig L: Altered tumor-cell glycosylation promotes metastasis. Front Oncol 4: 28, 2014.
8. Kaur S, Kumar S, Momi N, Sasson AR and Batra SK: Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol 10: 607-620, 2013.
9. Workman HC, Sweeney C and Carraway KL III: The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms. Cancer Res 69: 2845-2852, 2009.
10. Valque H, Gouyer V, Gottrand F and Desseyn JL: MUC5B leads to aggressive behavior of breast cancer MCF7 cells. PLoS One 7: e46699, 2012.
11. H oshi H, Sawada T, Uchida M, Saito H, Iijima H, Toda-Agetsuma M, Wada T, Yamazoe S, Tanaka H, Kimura K, et al: Tumor-associated MUC5AC stimulates in vivo tumorigenicity of human pancreatic cancer. Int J Oncol 38: 619-627, 2011.
12. Yamazoe S, Tanaka H, Sawada T, Amano R, Yamada N, Ohira M and Hirakawa K: RNA interference suppression of mucin 5AC (MUC5AC) reduces the adhesive and invasive capacity of human pancreatic cancer cells. J Exp Clin Cancer Res 29: 53, 2010.
13. Chauhan SC, Ebeling MC, Maher DM, Koch MD, Watanabe A, Aburatani H, Lio Y and Jaggi M: MUC13 mucin augments pancreatic tumorigenesis. Mol Cancer Ther 11: 24-33, 2012.
14. Maher DM, Gupta BK, Nagata S, Jaggi M and Chauhan SC: Mucin 13: Structure, function, and potential roles in cancer pathogenesis. Mol Cancer Res 9: 531-537, 2011.
15. Lakshmanan I, Ponnusamy MP, Das S, Chakraborty S, Haridas D, Mukhopadhyay P, Lele SM and Batra SK: MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene 31: 805-817, 2012.
16. Tinder TL, Subramani DB, Basu GD, Bradley JM, Schettini J, Million A, Skaar T and Mukherjee P: MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol 181: 3116-3125, 2008.
17. Gottfried E, Kreutz M and Mackensen A: Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev 19: 65-77, 2008.
18. Steinman RM: Decisions about dendritic cells: Past, present, and future. Annu Rev Immunol 30: 1-22, 2012.
19. Carlos CA, Dong HF, Howard OM, Oppenheim JJ, Hanisch FG and Finn OJ: Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J Immunol 175: 1628-1635, 2005.
20. Monti P, Leone BE, Zerbi A, Balzano G, Cainarca S, Sordi V, Pontillo M, Mercalli A, Di Carlo V, Allavena P, et al: Tumorderived MUC1 mucins interact with differentiating monocytes and induce IL-10highIL-12low regulatory dendritic cell. J Immunol 172: 7341-7349, 2004.
21. H iltbold EM, Vlad AM, Ciborowski P, Watkins SC and Finn OJ: The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J Immunol 165: 3730-3741, 2000.
22. Rughetti A, Pellicciotta I, Biffoni M, Bäckström M, Link T, Bennet EP, Clausen H, Noll T, Hansson GC, Burchell JM, et al: Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. J Immunol 174: 7764-7772, 2005.
23. Freire T, Lo-Man R, Bay S and Leclerc C: Tn glycosylation of the MUC6 protein modulates its immunogenicity and promotes the induction of Th17-biased T cell responses. J Biol Chem 286: 7797-7811, 2011.
24. Ishida A, Ohta M, Toda M, Murata T, Usui T, Akita K, Inoue M and Nakada H: Mucin-induced apoptosis of monocyte-derived dendritic cells during maturation. Proteomics 8: 3342-3349, 2008.
25. Andrianifahanana M, Moniaux N and Batra SK: Regulation of mucin expression: Mechanistic aspects and implications for cancer and inflammatory diseases. Biochim Biophys Acta 1765: 189-222, 2006.
26. Roy MG, Livraghi-Butrico A, Fletcher AA, McElwee MM, Evans SE, Boerner RM, Alexander SN, Bellinghausen LK, Song AS, Petrova YM, et al: Muc5b is required for airway defence. Nature 505: 412-416, 2014.
27. Sóñora C, Mazal D, Berois N, Buisine MP, Ubillos L, Varangot M, Barrios E, Carzoglio J, Aubert JP and Osinaga E: Immunohistochemical analysis of MUC5B apomucin expression in breast cancer and non-malignant breast tissues. J Histochem Cytochem 54: 289-299, 2006.
28. Buisine MP, Devisme L, Degand P, Dieu MC, Gosselin B, Copin MC, Aubert JP and Porchet N: Developmental mucin gene expression in the gastroduodenal tract and accessory digestive glands. II. Duodenum and liver, gallbladder, and pancreas. J Histochem Cytochem 48: 1667-1676, 2000.
29. Walsh MD, Clendenning M, Williamson E, Pearson SA, Walters RJ, Nagler B, Packenas D, Win AK, Hopper JL, Jenkins MA, et al: Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype. Mod Pathol 26: 1642-1656, 2013.
30. Berois N, Varangot M, Sóñora C, Zarantonelli L, Pressa C, Laviña R, Rodríguez JL, Delgado F, Porchet N, Aubert JP, et al: Detection of bone marrow-disseminated breast cancer cells using an RT-PCR assay of MUC5B mRNA. Int J Cancer 103: 550-555, 2003.
31. Tiscornia I, Sánchez-Martins V, Hernández A and Bollati-Fogolín M: Human monocyte-derived dendritic cells from leukoreduction system chambers after plateletpheresis are functional in an in vitro co-culture assay with intestinal epithelial cells. J Immunol Methods 384: 164-170, 2012.
32. Lu HP and Chao CC: Cancer cells acquire resistance to anticancer drugs: An update. Biomed J 35: 464-472, 2012.
33. Anguille S, Smits EL, Lion E, van Tendeloo VF and Berneman ZN: Clinical use of dendritic cells for cancer therapy. Lancet Oncol 15: e257-e267, 2014.
34. H egmans JP and Aerts JG: Immunomodulation in cancer. Curr Opin Pharmacol 17: 17-21, 2014.
35. Pandit TS, Kennette W, Mackenzie L, Zhang G, Al-Katib W, Andrews J, Vantyghem SA, Ormond DG, Allan AL, Rodenhiser DI, et al: Lymphatic metastasis of breast cancer cells is associated with differential gene expression profiles that predict cancer stem cell-like properties and the ability to survive, establish and grow in a foreign environment. Int J Oncol 35: 297-308, 2009.
36. Mimeault M, Johansson SL, Senapati S, Momi N, Chakraborty S and Batra SK: MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies. Cancer Lett 295: 69-84, 2010.
37. Kalra AV and Campbell RB: Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: Overcoming cellular barriers for therapeutic gain. Br J Cancer 97: 910-918, 2007.
38. Ren J, Agata N, Chen D, Li Y, Yu WH, Huang L, Raina D, Chen W, Kharbanda S and Kufe D: Human MUC1 carcinomaassociated protein confers resistance to genotoxic anticancer agents. Cancer Cell 5: 163-175, 2004.
39. Siragusa M, Zerilli M, Iovino F, Francipane MG, Lombardo Y, Ricci-Vitiani L, Di Gesù G, Todaro M, De Maria R and Stassi G: MUC1 oncoprotein promotes refractoriness to chemotherapy in thyroid cancer cells. Cancer Res 67: 5522-5530, 2007.
40. Skrypek N, Duchêne B, Hebbar M, Leteurtre E, van Seuningen I and Jonckheere N: The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. Oncogene 32: 1714-1723, 2013.
41. Kalra AV and Campbell RB: Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours. Eur J Cancer 45: 164-173, 2009.
42. Nath S, Daneshvar K, Roy LD, Grover P, Kidiyoor A, Mosley L, Sahraei M and Mukherjee P: MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes. Oncogenesis 2: e51, 2013.
43. Patankar MS, Jing Y, Morrison JC, Belisle JA, Lattanzio FA, Deng Y, Wong NK, Morris HR, Dell A and Clark GF: Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol Oncol 99: 704-713, 2005.
44. Belisle JA, Horibata S, Jennifer GA, Petrie S, Kapur A, André S, Gabius HJ, Rancourt C, Connor J, Paulson JC, et al: Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer 9: 118, 2010.
45. Freire T and Osinaga E: The sweet side of tumor immunotherapy. Immunotherapy 4: 719-734, 2012.